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5-Fluorouracil signaling through a calcium–calmodulin-dependent
pathway is required for p53 activation and apoptosis in colon
carcinoma cells
G Can1,3, B Akpinar1,3, Y Baran2, B Zhivotovsky1 and M Olsson1
5-Fluorouracil (5-FU) is an anti-metabolite that is in clinical use for treatment of several cancers. In cells, it is converted into three
distinct fluoro-based nucleotide analogs, which interfere with DNA synthesis and repair, leading to genome impairment and,
eventually, apoptotic cell death. Current knowledge states that in certain cell types, 5-FU-induced stress is signaling through a p53-
dependent induction of tumor necrosis factor-receptor oligomerization required for death-inducing signaling complex formation
and caspase-8 activation. Here we establish a role of calcium (Ca2þ ) as a messenger for p53 activation in response to 5-FU. Using a
combination of pharmacological and genetic approaches, we show that treatment of colon carcinoma cells stimulates entry of
extracellular Ca2þ through long lasting-type plasma membrane channels, which further directs posttranslational phosphorylation
of at least three p53 serine residues (S15, S33 and S37) by means of calmodulin (CaM) activity. Obstructing this pathway by the
Ca2þ -chelator BAPTA (1,2-bis(o-aminophenoxy)ethane- N,N,N’,N’-tetraacetic acid) or by inhibitors of CaM efficiently reduces 5-FU-
induced caspase activities and subsequent cell death. Moreover, ectopic expression of p53 S15A in HCT116 p53 / cells confirmed
the importance of a Ca2þ–CaM–p53 axis in 5-FU-induced extrinsic apoptosis. The fact that a widely used therapeutic drug, such as
5-FU, is operating via this pathway could provide new therapeutic intervention points, or specify new combinatorial treatment
regimes.
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INTRODUCTION
5-Fluorouracil (5-FU, Adrucil) is an anti-metabolite, which has been
used in clinical practice for over 40 years. Some of its primary
targets are colorectal and gastrointestinal cancers, but it is also
used in treatment of breast, head and neck, and ovarian
carcinomas. In cells, it is converted into three main fluoronucleo-
tide analogs: fluorodeoxyuridine monophosphate, fluorodeoxyur-
idine triphosphate and fluorouridine triphosphate, each able to
induce cellular stress by distinct mechanisms. Fluorodeoxyuridine
monophosphate acts as a covalent thymidylate synthase inhibitor,
resulting in a thymineless cell-state due to reduced deoxyuridine
monophosphate methylation. The lack of 2’-deoxythymidine
triphosphate follows by an accumulation of fluorodeoxyuridine
triphosphate and deoxyuridine triphosphate pools, which may
overwhelm steady-state repair systems that normally exclude
uracil from DNA. As a consequence of a depleted thymine pool,
forced incorporation of uracil and subsequent impairment of DNA
replication and repair may then trigger activation of specific cell
death pathways.1 It has also been suggested that loss of
carcinogenic properties in colon and breast cancer cell lines
may be caused by RNA stress through misincorporation of
fluorouridine triphosphate,2–4 thus inhibiting processes such as
rRNA maturation, splicing of pre-mRNA and post-transcriptional
modification of tRNAs.1 In comparison with the generally accepted
ATM (kinase ataxia telangiectasia mutated)/ATR (Rad3-related
protein)–Chk1/Chk2 (checkpoint kinases 1 and 2, respectively)–
p53 signaling pathway, leading to apoptotic cell death in response
to severe DNA damage, significantly less has been reported regarding
death signaling cascades originating from RNA damage, even though
it has been proposed that transcriptional stress also can lead to
p53 activation.5 However, despite the extensive use of 5-FU in the
clinic, the relative importance for each triggering point is not
clearly established. A plausible explanation for this ambiguity
can be that, as 5-FU and its metabolites have the potential to
strain several discrete molecular mechanisms, treatment outcome
is governed by the tumor cell context, which certainly differs
between cell types. In support of this principle are data demon-
strating a marked difference between 5-FU and its metabolite
fluorodeoxyuridine monophosphate in their effect on the cell
cycle progression in colon cancer, and the cell’s ability to generate
DNA double-strand breaks, monitored by conversion of H2AX into
its active form gH2AX.6 In addition, it seems that a cancer cell’s
efficacy to remove and repair DNA sites where uracil have been
incorporated highly dictates its sensitivity to 5-FU.7
Once initiated, apoptosis is executed by caspases and several
upstream regulatory factors, which direct their proteolytic activity,
have been defined as either tumor suppressors or oncogenes.8
Two main apoptotic routes exist, the extrinsic receptor-mediated
and the intrinsic mitochondrial pathways. Although in the former,
extracellular ligands stimulate members from the tumor necrosis
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factor (TNF) receptor family (CD95, TNF, DR4 or DR5) to form
death-inducing signaling complexes (DISCs) required for caspase-
8 activation, disruption of mitochondrial membrane integrity and
release of pro-apoptotic factors control the latter pathway.
Although the initial phases are characterized by distinct features,
these apoptotic pathways converge in the activation of effector
caspases (caspases-3, -6 and -7), which in turn target a broad
spectrum of cellular proteins, thereby predestining cells to
irreversible cell death. As a consequence of double-strand
breaks in genomic DNA, many chemotherapeutic agents in
current use have been reported to trigger apoptosis by the
intrinsic pathway. Engagement of this conduit usually requires p53
function and mutations within the gene, or abnormalities in
signaling events leading to its activation can produce multiple
drug-resistant phenotypes.9 However, 5-FU does not conform to
this rule but has instead been described to induce a
p53-dependent extrinsic, DISC-mediated apoptotic pathway.
Accordingly, in situ immunohistochemical analyses of clinical
colorectal cancer sections correlated with the tumor stage (stage
I–IV), and treatment response demonstrated that p53 and DR5
expression decreased progressively for each stage, suggesting
that these proteins are important markers of advanced tumors,
and that p53 appears as a prognostic factor to predict recurrence-
free survival.10 It was also shown that inducible silencing of DR5 in
mice led to accelerated growth of bioluminescent tumor
xenografts and conferred 5-FU-resistance.11 Similar data have
been provided by using tumor cell lines, although conflicting
evidences exist postulating DR4, DR5 or CD95 as the regulatory
receptor for caspase-8 activation and apoptosis.12–14 Interestingly,
death receptor ligand does not seem to be required for DISC
formation in this particular apoptosis pathway.12 Most DR5
expression studies in clinical tumor sections do not
experimentally verify whether the death receptor is induced as a
consequence of chemotherapy, or if it is a response to
tumorogenesis. On the other hand, an examination of the
response of three human colon tumors to TNF-related
apoptosis-inducing ligand (TRAIL) alone and in combination with
chemotherapy drugs, using SCID mice engrafted with intact
patient surgical colorectal cancer specimens, revealed that tumors
treated with carnitine palmitoyltransferase-11 (CPT-II) showed
increased membrane expression of DR5, also suggesting that
CPT-II may increase sensitivity to TRAIL by upregulation of
DR5.15 In the present study, we extend the knowledge
concerning 5-FU-induced cell death and introduce a calcium–
calmodulin (Ca2þ–CaM)-dependent signaling event that is
required for specific phosphorylation-mediated activation of p53
and subsequent DISC activity, events that are essential for
5-FU-induced apoptosis.
RESULTS
DR5 but not CD95 facilitates apoptosis induced by 5-FU in HCT116
cells
Previously, we described a pronounced p53-dependent upregula-
tion of CD95 in 5-FU-treated HCT116 cells.16 In addition, using the
same experimental settings, CD95–DISC formation was revealed
by immunoprecipitation. However, as shown by immunostaining,
in response to 5-FU, both TNF-family receptors DR5 and CD95 are
accumulated in the plasma membrane (Figure 1a), indicating that
either one of them or both could have a vital role for efficient
apoptosis. As conflicting evidences exist in this matter,12,13,17 we
decided to assess the contribution of each individual receptor to
initiator caspase-8 and effector caspase-3 activation by means of
small interfering RNA (siRNA) technology (Figures 1b and c). This
experimental approach clearly demonstrated that DR5 but not
CD95 is the sole receptor required for caspase-8 activation and
further processing of caspase-2 and effector caspase-3 upon
treatment with 5-FU. In addition, isolation of membrane protein
fractions from untreated and induced cells revealed that in
response to 5-FU accumulation of DR5 and DISC components,
Fas-associated protein with death domain (FADD) and caspase-8
occur in plasma membranes (Figure 2a). DISC non-associated
caspase-7, on the other hand, remained in cytosol irrespectively of
treatment. As we used a protocol in which the total membrane
protein pool was isolated, TOM 40 (translocase of the outer
mitochondrial membrane) and tubulin served as a marker for
fractionation efficiency. To rule out the existence of DISC compo-
nents in cellular membranes other than the plasma membrane,
obtained results were confirmed using immunostaining with specific
antibodies targeting DR5 and FADD (Figure 2b). Moreover, as a
correspondent localization pattern was not observed in HCT116
p53 / cells using the same incubation time, we concluded
that an efficient accumulation of DISC components DR5, FADD
and caspase-8 in plasma membranes of 5-FU-treated cells is a
p53-dependent or -facilitated event. Thus, in agreement with
some previous reports,11,12 these results indicate the DR5-receptor
as a p53-dependent mediator of 5-FU-induced apoptosis, also
suggesting that the CD95–DISC, formed for still unidentified
reason(s), remains inactive with respect to caspase-8 activation, or
that contribution of this complex is insignificant.16
Analysis of potential regulatory factors upstream of DR5–DISC
formation
In contrast to classical extrinsic death pathways triggered by
ligands of the TNF family, 5-FU-induced apoptosis most certainly
emerges from either DNA or RNA damage. The question relating
to how initial drug-triggering points are transduced to DISC
formation and caspase-8 activity is indeed intriguing. p53 is
obviously an important factor for the process but a detailed
description of signaling events originating from 5-FU-induced
cellular stress leading to p53 activity and subsequent DR5
oligomerization is to a large extent still lacking in current
literature.9,16 Therefore, a panel of inhibitors, including
Ca2þ -chelator BAPTA (1,2-bis(o-aminophenoxy)ethane-N,N,N’,N’-
tetraacetic acid), RIP1-kinase inhibitor NEC1, the antioxidant
Trolox, pepstatin A, an inhibitor of acid proteases and the
cathepsin B inhibitor CA-074, was added in combination with
5-FU to HCT116 cells, to target potential upstream controlling
conduits (Figure 3a). Among the inhibitors used, three effectively
abrogated effector caspase-3 processing. Two of these, pepstatin
A and CA-074, are silencing lysosomal protease activity. However,
neither of them had any effect on the most apical caspase-8
activation. Hence, we concluded that lysosomal proteases indeed
have a role in 5-FU-induced apoptosis but appear to function as
an enhancer of effector caspase activity, downstream of DISC
formation. This is well in agreement with a recent report showing
that lysosomal membrane permeability and the cytosolic release
of cathepsins B, L and D indirectly depend on Bax/Bak and
components of the apoptosome.18 In comparison, BAPTA had a
profound effect also on caspase-8 processing, indicating Ca2þ as a
messenger acting upstream of the caspase cascade. Moreover,
although the 5-FU-induced p53 level remained unaffected in the
presence of BAPTA, phosphorylation of S15 was reduced
considerably, thus positioning the effect of Ca2þ in advance of
p53 posttranslational modifications (Figure 3a and Supplementary
Figure S1).
By using lentiviral-mediated transfer of wild-type (wt) and
mutated p53 cDNAs in p53 knock-out HCT116 cells, the p53 S15
phospho site was previously implicated in the apoptotic response
to 5-FU, as determined by measurement of subG1 cells after
propidium iodide staining.19 Here, by taking advantage of the
same methodology, we were able to further specify that in
comparison with reintroduced wt p53, the S15A mutation
abrogates DISC-facilitated caspase-8 processing and downstream
cleavage of poly (ADP-ribose) polymerase (PARP; Figure 3b).
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Figure 1. Both death receptors DR5 and CD95 translocate to plasma membranes in response to 5-FU treatment, but only silencing of the
former protein reduces the processing of apical and effector caspases. HCT116 control cells and cells induced with 5-FU for 20 h were fixed
in 4% formaldehyde for 20min and exposed to specific antibodies targeting either CD95 or DR5 (a). Cell nuclei were visualized by DAPI
(4’,6-diamidino-2-phenylindole). The effect of 5-FU with respect to processing of caspases -8, -2 and -3 was analyzed by SDS–PAGE, using total
lysates from cells in which either DR5 (b) or CD95 (c) had been silenced by means of siRNA transfections. Non-targeting control siRNA was
used to exclude the possibility that transfections per se interfered with analysis outcome and glyceraldehyde 3-phosphate dehydrogenase
was used as a control for equal loading of samples. Processed caspase fragments and isoforms of DR5 are indicated with asterisks.
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Figure 2. DISC-related factors accumulate in plasma membranes in a p53-dependent manner as a response to 5-FU treatment. HCT116 cells
were treated as indicated in figures and subsequently fractionated, generating membrane and cytosolic protein lysates, which were analyzed
by SDS–PAGE. Western blot membranes were next probed with antibodies directed to DISC-associated proteins DR5, FADD and caspase-8 (a).
Detection of TOM 40 and tubulin served to indicate the purity of membrane and cytoplasmic fractions, respectively. Exposure of the DISC
non-related caspase-7 was used as a negative control. Equal amount of protein material was loaded into each lane. Processed caspase
fragments are indicated with asterisks. To confirm the presence of the DISC in plasma membranes and to examine the significance of p53 for
translocation of DISC proteins to plasma membranes, HCT116 wt and HCT116 p53 / cells were treated as indicated, fixed in
paraformaldehyde and analyzed by indirect immunofluorescence using antibodies targeting DR5 and FADD (b). Cell nuclei were visualized by
DAPI (4’,6-diamidino-2-phenylindole).
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With prolonged 5-FU treatment, it has not escaped our notice
that also HCT116 p53 / cells undergo a DR5- and caspase-8-
dependent cell death. In fact, DR5 is correspondingly upregulated
in these cells, but to a lesser extent compared with the parental
cell line (manuscript in preparation). As neither BAPTA nor any of
the other inhibitors tested obstructed the weak caspase-3 activity
detected in HCT116 p53 / cells 48 h post 5-FU treatment, we
concluded that Ca2þ primarily exerts its effect on p53 activity as a
response to stress induced by 5-FU (Figure 3c).
The Ca2þ -level in HCT116 cells is enhanced in response to 5-FU
treatment
Ca2þ is a ubiquitous second messenger involved in many cellular
processes, including cell death.20,21 Ca2þ fluxes from the
extracellular space are determined by the activity of voltage-
operated, receptor-operated and store-operated membrane
channels that normally are under tight control. Elevated Ca2þ
level in the cytoplasmic compartment can also occur as a result of
release from the endoplasmic reticulum, which is the major
organelle involved in Ca2þ homeostasis. Changes in the intra-
cellular Ca2þ levels in response to 5-FU treatment in HCT116 cells
were monitored by using the Fluo-4AM fluorescent indicator. By
fluorescence-activated cell sorting, we detected an increase in
intracellular Ca2þ at 4 h, and a further enhancement at 5 h post
treatment (Figure 4a). After 5 h, increased level of Ca2þ remained
up to 15h, which is the time point when initiation of caspase
processing can be detected by SDS–polyacrylamide gel electro-
phoresis (PAGE; Figure 4b and ref 16, respectively). Examination of
cellular Ca2þ by time-lapse confocal microscopy was then
performed, and influx commencement noticed as early as 1.5 h
after addition of 5-FU (Figure 4c). This is well in advance of the p53
S15 phosphorylation, which could be detected by western blotting
5h post induction (Figure 4d). Thus, these data support our findings,
indicating Ca2þ as a regulatory factor acting upstream of p53 activity
in response to 5-FU. There are, however, some parameters that
have to be considered in this respect. First, western blotting can
be a sensitive or insensitive technique, depending on the specific
antibody used. Thus, activation of p53 as a consequence of S15
phosphorylation may occur earlier than what SDS–PAGE results
predict. Second, most likely, a critical threshold concentration of
Ca2þ must be reached to trigger subsequent p53 activity. By our
measurements, it is impossible to specify this threshold limit but a
qualified guess would be that it is reached between 1.5 and 4 h
post induction. Still, irrespectively of these uncertainties, elevation
of Ca2þ and p53 activity, as determined by S15 phosphorylation,
remains co-ordinated sequence of events.
Extracellular Ca2þ influx is required for 5-FU-induced p53
phosphorylation and caspase activation
To determine the source of Ca2þ required for apoptotic signaling
in 5-FU-treated HCT116 cells, the following experiments were
performed. To begin with, cells were cultured and treated in
Ca2þ -free media and then analyzed with respect to p53 S15
phosphorylation and appearance of apoptotic markers, including
caspase processing and PARP cleavage (Figures 5a and b). As the
lack of environmental Ca2þ had a clear effect on all parameters
tested, reducing phospho-p53 activation even more efficiently
than BAPTA and decreasing caspases-3 and -8 processing, as well
as PARP cleavage to control cell levels, we concluded that
extracellular Ca2þ is the primary source required for develop-
ment of specific apoptotic processes in 5-FU-treated HCT116
cells. Besides, verapamil, an inhibitor of long lasting (L)-type
Ca2þ plasma membrane channels abrogated 5-FU-induced
p53 S15 phosphorylation, as well as caspase-3 and -8 activities,
in a concentration-dependent manner (Figure 5c). Although
these data clearly state that a 5-FU-dependent cellular influx
of Ca2þ is an early event obligatory for at least one p53
posttranslational modification, they do not entirely exclude the
possibility that endoplasmic reticulum-derived Ca2þ has a role.
Ca2þ -induced Ca2þ release is a process that amplifies cytosolic
Ca2þ through either inositol 1,4,5-trisphosphate or different
isoforms of sarco/endoplasmic reticulum ryanodine receptors.
Although primarily associated with the physical control of
muscle cells and neurons, Ca2þ -induced Ca2þ release has also
been implicated in apoptosis regulation.22 To investigate whether
the external Ca2þ signaling relays on the internal Ca2þ -induced
Ca2þ release excitable system for optimal phospho-p53
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Figure 3. Chelation of Ca2þ interferes with p53 S15 phospho
activation and initiation of the apoptotic cascade in 5-FU-induced
HCT116 cells but not in HCT116 p53 / cells. HCT116 wt (a) and
p53 / cells (c) were left untreated or induced with 5-FU as
indicated, either alone or in combination with potential chemical
inhibitors of DISC-mediated apoptosis. Cells were collected and total
cell lysates were analyzed by SDS–PAGE. Following the blotting
procedure, membranes with material originating from HCT116 wt
cells were examined by using antibodies directed to caspase-8,
processed caspase-3, cleaved PARP, p53 and its phospho activation
of S15, whereas membranes with separated HCT116 p53 / cell
lysates were analyzed with respect to processed caspase-3 as a
control for the p53-regulating properties of Ca2þ . Reintroduction of
wt p53 and S15A-mutated p53 to p53-deficient HCT116 cells by
means of lentiviral transduction served to confirm that the S15
phospho site is important for proper DISC-mediated caspase-8
processing and cleavage of PARP (b). In addition to PARP and
caspase-8, the membrane in b was probed with antibodies targeting
p53 and phospho-modified S15 to control correct expression of
cDNAs. Probing of glyceraldehyde 3-phosphate dehydrogenase
served as a control for equal loading of samples. Two conditions of
BAPTA treatment and 5-FU co-treatment, 5 mM for 48 h or 10 mM
added 24 h post 5-FU induction, were performed in HCT116 p53 /
cells to avoid toxicity. Results for BAPTA are decorated (a and c).
Processed caspase fragments are indicated with asterisks.
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activation, intracellular Ca2þ stores were depleted by incubation
of cells in the presence of thapsigargin for 1 h in advance of 5-FU
treatment (Figure 5d). As the phospho activation of p53 S15
remained unaltered in 5-FU and thapsigargin co-treated cells
compared with 5-FU control samples, we concluded that Ca2þ
released from the endoplasmic reticulum does not significantly
contribute to 5-FU-induced cell death signaling. Together, these
data indicate that the Ca2þ required for early apoptotic signaling
occurring in response to 5-FU originates from extracellular
sources, and that translocation of ions through the plasma
membranes at least partly is mediated by L-type Ca2þ channels.
CaM is a transitional factor for conducting Ca2þ signaling to p53
activity in response to 5-FU
To maintain normal cellular control and tissue integrity, p53 is
regulated at the posttranslational level by protein–protein
interactions and covalent modifications, including phosphoryla-
tion at over 20 phospho-acceptor sites.23 The reports examining
the role of kinases able to modulate p53 activity have led to much
controversy within the field, but the general view seems to be that
one or several kinases may act on the same residue in a cell- or
stimuli-specific manner. Indeed, several acceptor sites of p53 are
phosphorylated in response to 5-FU (Figure 6b) and, most likely,
the majority of them contribute to treatment outcome in one
or another way. However, our focus was to decipher the Ca2þ -
dependent pathway described, and to analyze its importance
for DR5-mediated cell death. Among kinase-dependent activity
pathways acting on p53, only two are controlled by Ca2þ
signaling. One of them involves serine/threonine kinase members
included in a subgroup of the protein kinase C (PKC) family
termed the classical group encompassing PKCs-a, -bI, -bII and
-g.24–26 The other one is facilitated by the ubiquitous Ca2þ -
sensing protein CaM and occurs through activation of members
contained in the superfamily of CaM-dependent kinases.27–29 As a
selective inhibitor of PKC (PKC412) did not attenuate p53 S15
phosphorylation in any of the concentrations tested, we
concluded that this kinase did not contribute to the 5-FU-
induced and Ca2þ -dependent events leading to p53 activity.
Interestingly, in presence of PKC412 processing of caspases-3 and
-8 was inhibited, but obviously in a manner independent of the
p53 S15 residue (Figure 6a). In sharp contrast, we observed
abrogation of p53 S15 and S33 phosphorylations in parallel with
decreased processing of caspases occurring in a concentration-
dependent manner when two different CaM inhibitors, calmida-
zolium chloride or fluphenazine-N-2-chloroethane, were added to
HCT116 cells in combination with 5-FU (Figure 6b). A decrease in
p53 S46 phosphorylation was also noted, but only in cells
pretreated with calmidazolium chloride and not fluphenazine-N-2-
chloroethane. S37 phosphorylation was indeed blocked using
both inhibitors but in a concentration-independent pattern
dissimilar to reduction of caspase processing and phospho
activation of S15 and S33, thus indicating this particular phospho
site as being less important for the apoptotic process examined.
Phosphorylation of the S6, 9 and 382 sites, on the other hand,
remained unaffected in the presence of CaM inhibitors.
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Figure 4. Increase in intracellular Ca2þ occurs as an immediate and persistent response to 5-FU, which is timely co-ordinated with the S15
phospho activation and stabilization of the tumor suppressor p53 in HCT116 cells. The Ca2þ probe Fluo-4AM was added to cells 30min in
advance of 5-FU and a comparison of Ca2þ levels was performed in between non-treated and treated samples. Elevated fluorescent intensity
indicating elevated Ca2þ levels was observed by fluorescence-activated cell sorting using the FL-1H channel in cells treated for 4 and 5 h (a),
as well as in cells induced for 15 h (b). Examination of the Fluo-4AM fluorescent signal by confocal microscopy revealed a rise in intracellular
Ca2þ as early as 90min post treatment (c). Analysis of S15 phosphorylation and stabilization of p53 using SDS–PAGE indicated activation of
the tumor suppressor at 5 h post 5-FU treatment (c). Tubulin served as a marker for equal loading.
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Interestingly, DR5 protein expression levels remained in the presence
of CaM inhibitors, indicating mechanisms separated from death
receptor transactivation to be involved in p53-mediated triggering
of caspase-8 (data not shown). Other factors, which have been
defined as regulators of p53 posttranslational modifications and
activation, include Chk2 and ATM.24,30,31 By using HCT116 Chk2 /
cells and a specific inhibitor of ATM (KU55933), we could conclude
that these factors did not contribute significantly to any of the
5-FU-induced p53 phosphorylation events analyzed. Still, in
Chk2 / cells, processing of caspases-3 and -8 occurred at a
slower rate compared with the parental cell line, implicating this
factor in 5-FU-induced apoptosis by a yet unknown mechanism
(Figure 6c). Using KU55933 in combination with 5-FU, on the other
hand, drastically increased apoptotic rate as determined by
caspase-3 processing and PARP cleavage (Figures 6d and e).
Interestingly, the synergistic effect with respect to effector caspase
processing induced by the ATM inhibitor occurred in the absence
of a further increased apical caspases-8 activity, as compared with
samples where 5-FU was used alone (Figure 6e), indicating that
combinatorial treatment using 5-FU and KU55933 triggers an
additional cell death mechanism, which is separated from the
DR5–DISC. At later time points of 5-FU-induced cell death,
KU55933 indeed obstructs several tested phospho-p53 modifica-
tions, except S33 and only partly S15. Importantly, at these time
points, KU55933 control samples also contained active p53 and
were positive for several apoptotic markers implying difficulties of
data interpretation (data not shown). Validation of data obtained
using KU55933 was generated by siRNA methodology (Figures 6f–g).
In summary, it is likely that 5-FU stimulates apoptosis through a
Ca2þ–CaM-dependent pathway, which in turn directs the DR5–
DISC activity through p53. However, the specific kinase directed
by Ca2þ–CaM with importance for discrete p53 phosphorylations
remains unidentified. Interestingly, transactivation and dimeriza-
tion of the DR5, analyzed by standard and non-denaturing
SDS–PAGE, respectively, occurring in response to 5-FU, was
neither affected by BAPTA nor calmidazolium chloride, indicating
that p53 supports caspase-8 processing by mechanisms separated
from these events (Figure 6h). It should also be noted that BAPTA
and calmidazolium chloride, but not fluphenazine-N-2-chlor-
oethane, diminished 5-FU-mediated autophagy, as determined
by a reduction of the major selective autophagic substrate p62. As
all three inhibitors interfere with activation of the caspase cascade,
these results exclude autophagy to be functionally connected to
the signaling route investigated (data not shown).
5-FU-induced Ca2þ deregulation is signaling through a p38MAPK-
independent pathway
In a recent report, it was suggested that p38MAP kinase
(p38MAPK) activation is a key determinant in the cellular response
to 5-FU. As inhibition of p38MAPKa by the SB203580 compound
or by short hairpin RNA interference obstructed 5-FU-associated
apoptosis while autophagy was promoted, p38MAPK was
suggested to act as a potential regulator of p53 and the balance
between apoptotic and autophagic processes.32 In turn, the
mammalian mitogen-activated protein (MAP3K) apoptosis signal-
regulating kinase 1 (ASK1) is a pivotal component in cytokine- and
stress-induced apoptosis, which may act as a critical intermediate
of Ca2þ signaling between Ca2þ–CaM-dependent protein kinase
type II and p38MAPK33,34 It is, therefore, possible that the Ca2þ -
dependent apoptotic pathway disclosed by our data merges with
the previously defined p38MAPK pathway.32 To verify this
hypothesis, 5-FU-treated HCT116 cells were pre-incubated with
BAPTA and the p38MAPKa inhibitor SB203580, either separately or
in combination (Figure 7). Transactivation of the cyclic AMP-
dependent transcription factor-3 (ATF3), a target protein of both
the p38MAPK and the CaM/calcineurin pathway acting via the
myocyte-specific enhancer factor 2a functioned as a control for
drug efficiency. Indeed, each compound efficiently obstructed
effector caspase-3 processing, and a synergistic effect was
revealed in combinatorial treatment. Caspase-8 processing, on
the other hand, was only blocked by the addition of BAPTA but
not of SB203580. Moreover, although only a minor destabilization
of p53 could be observed in samples pretreated with BAPTA and
no effect was observed with SB203580, they provided a synergistic
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Figure 5. Influx of Ca2þ from extracellular sources, but not Ca2þ
released from the ER, is required for efficient phospho activation of
p53 and further induction of DISC-mediated apoptosis. HCT116 cells
were exposed to 5-FU, either in combination with BAPTA using
standard culture medium (Dulbecco’s modified Eagle’s medium)
or alone using Ca2þ -free Dulbecco’s modified Eagle’s medium.
Inactive (1/2) BAPTA was used as a negative control. Cells were
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activation of p53 S15 (a), caspase-8, active caspase-3 and cleaved PARP
(b) are shown. The importance of extracellular Ca2þ for efficient p53
activation (S15) and caspase-3 and -8 activities were confirmed in
immunoblotting by co-treatment of 5-FU and verapamil, an inhibitor
of L-type Ca2þ plasmamembrane channels (c). Immunoblot analysis of
lysates from cells treated with thapsigargin 1 h in advance of 5-FU
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effect with respect to this event resulting in levels of the tumor
suppressor, which were similar to controls. In conclusion, although
these data do not exclude the possibility that pathways resulting
from p38MAPK activity and cellular Ca2þ deregulation share some
common features, they certainly expose features of specificity,
especially with respect to the DR5-mediated caspase-8 activation,
which seems to involve Ca2þ but not p38MAPK. Moreover,
effective stabilization of p53 seems to require posttranslational
modifications originating from both signaling circuits.
DISCUSSION
The association between alterations in intracellular Ca2þ home-
ostasis and various stages of the apoptotic signaling cascade is
indisputable.35 In the present report, we uncover a new Ca2þ -
dependent apoptotic mechanism, which occurs in response to
5-FU and is mediated through CaM and p53 activities, regulating
the caspase cascade via the DR5–DISC and initiation of caspase-8
processing (Figure 8). Importantly, the signaling route described
could also be initiated by low doses of 5-FU, and the response of
human A549 lung adenocarcinoma cells was similar to the one
revealed in HCT116 cells (Supplementary Figures S3 and S2). The
generality of the pathway was further validated by including the
human breast adenocarcinoma MCF-7 and the human ovarian
carcinoma CAOV-4 cell lines into the study. Both responded
to 5-FU treatment in terms of p53 S15 phospho activation and
in the case of CAOV-4, also with an accumulation of DR5 and
processed caspase-3. As MCF-7 cells are caspase-3-deficient, an
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with S15 and S33 p53 phosphorylation. HCT116 cells were treated with 5-FU, either alone or in combination with inhibitors to protein kinase C
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investigation of the common apoptotic markers would be
misleading and was, therefore, not performed. Nevertheless, both
BAPTA and the CaM-inhibitor calmidazolium chloride clearly
abrogated the p53 S15 phosphorylation in these cells. In contrast,
although caspase-3 processing and DR5 transactivation were
obstructed by the same set of inhibitors in 5-FU-induced CAOV-4
cells, no effect was detected with respect to phospho activation of
p53 S15. Thus, the Ca2þ–CaM-mediated pathway might direct
other p53 phospho sites, or a separate mechanism required for
activation of the caspase cascade in this particular cell line (data
not shown).
Evidences obtained from a wide variety of preclinical experi-
mental studies, epidemiological findings and a few human clinical
trials support the view that dietary Ca2þ can modulate and inhibit
colon carcinogenesis.36 More interesting for the present study,
however, is the fact that adjuvant chemotherapy combining 5-FU
with Ca2þ folinate can alter the natural history of resected colon
cancer and offer an overall survival advantage in comparison with
other 5-FU-based regimens or with 5-FU alone.37
According to the literature, 5-FU and its metabolites have
several direct or indirect target points within cells, including DNA,
RNA and ribosomal biogenesis.1,4,38 Although DNA lesion
represent the most well-documented incident causing activation
of p53, recent reports also involve transcriptional stress and
ribosome damage in signaling events, leading to specific
posttranslational modifications of the tumor suppressor.5,34 An
accumulation of double-strand breaks in response to 5-FU in
HCT116 cells is evident as the number of gH2AX foci observed by
immunostaining increased over time (data not shown), but our
data involving ATM inhibition by KU55933 and Chk2-deficient cells
excluded the DNA damage response as a starting point for Ca2þ -
induced p53 phospho activation. Thereby, we are not arguing that
apoptosis proceed irrespectively of the DNA damage response. It
is important to remember that all p53 sites analyzed were
phosphorylated in response to 5-FU, but only three were silenced
in the presence of inhibitors to CaM. The origin of the stress
response that is able to deregulate cellular Ca2þ in our settings is,
however, still unclear and further investigations are required to
solve this issue. The combined effect of KU55933 and 5-FU
augmented effector caspase-3 activity compared with samples
treated with 5-FU alone, whereas no difference was detected for
the more upstream caspase-8 activity. These results are in good
agreement with a recent report, suggesting that KU55933 may
target cancer cells resistant to traditional chemotherapy due to
aberrant activation of Akt.39 Experiments using verapamil were
indicating high-voltage-gated Ca2þ channels of the L-type as the
entry point for extracellular Ca2þ influx in response to 5-FU. This is
well in line with the fact that the elevated Ca2þ level appeared as
an immediate reaction to treatment and then remained until
onset of the caspase cascade. The a1-subunit, which contains the
voltage-sensing machinery and the drug/toxin-binding sites, form
the Ca2þ -selective pore and is the primary factor operating in
high-voltage-gated Ca2þ channels. Out of ten a1-subunits
described in humans, four are specific for L-type channels, and
current work aims to identify whether one or several a1-subunits
are required for the process described, and to further specify the
link between 5-FU and L-type high-voltage-gated Ca2þ channels.
Here, two possibilities exist. Either 5-FU-specific cell stress induces
a still unidentified signaling cascade activating one or several
L-type pores, alternatively, 5-FU or its metabolites act directly on
these pores. In line with our study and supporting the fact that
at least the CaM-directed p53 S15 phospho-modification is
important for 5-FU-induced apoptosis are findings coming from
expression at physiological levels of p53 mutants in p53 knock-out
HCT116 cells. Compared with cells expressing exogenous wt p53,
the apoptotic response to 5-FU was more than 50% reduced in
cells expressing S15A mutant p53, whereas a serine to alanine
replacement on the 33 amino acid residue had no profound effect
on cell death.19
BAPTA or CaM inhibitors reduced the capacity of 5-FU to induce
apical caspase-8 processing through DR5–DISCs. Still, oligomeriza-
tion of DR5 occurred also in the presence of these agents with an
efficiency similar to cells treated with 5-FU alone. Evidently, a
candidate target molecule for the pathway described is the
cellular FLICE inhibitory protein (cFLIP), a catalytically inactive
homolog of caspases-8 and -10 able to prevent their activation by
obstructing binding sites on the DISC.40 Thus, deregulation of
cFLIP is a prerequisite for efficient initiation of DISC-mediated
caspase-8 processing. Suppression of the cFLIP short and long
isoforms in response to 5-FU occurred, however, not only in a p53-
but also in a Ca2þ -independent fashion as determined by
analyzing its expression level in the presence of BAPTA and in
HCT116 p53 / cells (Supplementary Figure S4 and S5). In fact,
this is in agreement with recent reports showing that chemother-
apy-induced downregulation of cFLIP splice forms occurs in cell
lines irrespectively of their p53 status and, more specifically, that
ATM kinase activity is required to trigger 5-FU- and neocarzinos-
tatin-induced and p53-independent cFLIP downregulation, which
in turn sensitized hepatocellular carcinoma cell lines to TRAIL.41,42
Identification of the factor regulated by the Ca2þ–CaM–p53 axis
described in this report conducting DR5–DISC activity thereby
remains.
Previously, we suggested CD95 as an upstream regulatory
element required for initiation of the caspase cascade in
response to 5-FU.16 This assumption was based on a promi-
nent p53-dependent upregulation of this death receptor and
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co-immunoprecipitation studies. However, by means of RNA
interference methodology, the present report concludes that
DR5 is more important with respect to caspase-8 activity and
apoptotic proceedings. On the basis of these results, a possible
explanation for this inconsistency may be that the FAS–DISCs
formed in the experimental system analyzed contributes insigni-
ficantly to the cell death process examined.
As TRAIL can induce apoptotic cell death in a variety of tumor
cells by engaging specific death receptors, DR4 and DR5, whereas
having low toxicity towards normal cells, it has been postulated as
a future therapeutic option.43 Our present report, as well as data
obtained by others, is demonstrating that 5-FU-induced cell death
also involves DR5. Disclosing 5-FU-induced death pathways might,
therefore, conform to the highly interesting research field of TRAIL
in tumor treatment and to processes relating to development of
TRAIL resistance. In addition, although Ca2þ previously has been
implicated in various cell death pathways, the novelty of our data
indicating that the Ca2þ–CaM signaling is required for apoptosis
triggered by 5-FU in certain cancer cell types must be emphasized.
Response rates for 5-FU in advanced colorectal cancer are modest,
and although combinatorial treatment using chemotherapeutic
agents, such as oxaliplatin and irinotecan, has improved survival
rates there is a need for new curative strategies. The fact that a
widely used drug, such as 5-FU, is signaling by this mean may
provide new therapeutic intervention points for combinatorial
treatment regimens, as well as explanations for cell resistance.
MATERIALS AND METHODS
Cell culture
The HCT116 parental cell line and its variants, deficient in p53 or Chk2 (a gift
from Professor Bert Vogelstein) were cultured in Dulbecco’s modified Eagle’s
medium and the A549 cell line in RPMI1640 medium, both supplemented
with 10% heat-inactivated fetal bovine serum and PenStrep (100U/ml
penicillin, 100mg/ml streptomycin). Cell culture reagents were purchased
from GIBCO (Invitrogen, San Diego, CA, USA). Treatment of cells with the
anti-metabolite 5-FU (Teva Pharmaceutical Industries, Petach Tikva, Israel)
was performed at a concentration of 768mM, unless otherwise stated. Usage
of thapsigargin, BAPTA (Invitrogen), Verapamil, pepstatin A (Sigma-Aldrich, St
Louis, MO, USA), calmidazolium chloride, fluphenazine-N-2-chloro-
ethane (Santa Cruz Biotechnology, Santa Cruz, CA, USA), PKC412 (Novartis
International, Basel, Switzerland), ATM inhibitor KU55933, p38 MAPK inhibitor
SB203580 (Selleck Chemicals LLC, Houston, TX, USA), CA-074 Me, Trolox,
Necrostatin-1 and its inactive control Necrostatin-1i (Merck, Darmstadt,
Germany) were performed as indicated in figures.
Gel electrophoresis and immunoblotting
Cells were treated as indicated, washed in phosphate-buffered saline and
lysed for 5min in Complete Lysis-M (Roche Diagnostics, Mannheim, Germany)
containing 1 Complete Protease Inhibitor Cocktail (Roche Diagnostics)
and 1 Phosphatase inhibitor Cocktail 2 (Sigma-Aldrich). The BCA Protein
assay (Thermo Fisher Scientific, Lafayette, IN, USA) was used to determine
protein concentration. Equal quantities from each sample were subjected
to SDS–PAGE and electroblotted to nitrocellulose membranes (Bio-Rad
Laboratories, Hercules, CA, USA). Membranes were then blocked and probed
with the primary antibody of interest at 4 1C overnight. Finally, membranes
were incubated with horseradish-peroxidase-conjugated secondary antibodies
for 1 h at room temperature, revealed by enhanced chemiluminescence
(GE Healthcare Biosciences, Uppsala, Sweden) and exposed to SuperRX
X-ray films (Fujifilm Corporation, Tokyo, Japan). To analyze DR5 clustering,
cells were lysed for 20min on ice using a non-reducing Triton buffer
(20mM Tris HCl (pH 7.5), 150mM NaCl, 10% Glycerol, 0.2% Triton X-100 and
1mM EDTA) supplemented with protease and phosphatase inhibitors.
Samples were then treated with Benzonase nuclease (Sigma-Aldrich) for
15min at room temperature, mixed in non-reducing sample buffer and
subjected to SDS–PAGE.
Immunofluorescence
HCT116 and HCT116 p53 / cells were seeded on coverslips, treated as
indicated in figures and then fixed for 30min, using 4% formaldehyde in
phosphate-buffered saline at 4 1C. Permeabilization and blocking was done
in phosphate-buffered saline containing 0.3% Triton X-100 and 1% bovine
serum albumin for 1 h. Incubations with primary antibodies (1:400) and
secondary antibodies (1:200) were performed at 4 1C overnight and at
room temperature for 60min, respectively. Nuclei were counterstained
with Hoechst 33,342 (10mg/ml in phosphate-buffered saline). Finally, the
coverslips were mounted using Vectashield H-1000 (Vector Laboratories Inc.,
Peterborough, UK) and examined under a Zeiss LSM 510 META confocal
laser scanner microscope (Carl Zeiss MicroImaging, Go¨ttingen, Germany).
Antibodies
The following primary antibodies were used in western blotting: p53 mAb,
clone DO1; glyceraldehyde 3-phosphate dehydrogenase polyclonal antibody
(pAb), Tom 40 pAb, CD95 pAb, AMP-dependent transcription factor-3 pAb
(Santa Cruz Biotechnology), phospho-p53 pAbs (Ser6, 9, 15, 33, 37, 46 and
382), cleaved-caspase-3 pAb, ATM monoclonal antibody (mAb), clone D2E2;
phospho-H2A.X (Ser139) pAb (Cell Signaling, Danvers, MA, USA), a-Tubulin
mAb, clone B-5-1-2; DR5 pAb (Sigma-Aldrich), PARP mAb, clone 4C10-5; Bax
mAb, clone 6A7; caspase-7 mAb, clone B94-1; caspase-2 mAb, clone 35 (BD
Biosciences, Franklin Lakes, NJ, USA), cFlip mAb, clone Dave-2 (Alexis, San
Diego, CA, USA), FADD pAb (Upstate Biotechnologies, Lake Placid, NY, USA)
and caspase-8 mAb, clone C15 (kindly provided by Professor PH Krammer
and Dr I Lavrik, German Cancer Research Center, Heidelberg, Germany).
Analysis of DR5 in immunofluorescence was performed using the mAb clone
11/B4 (kindly provided by Professor L Andeˇra, Academy of Sciences of the
Czech Republic, Prague, Czech Republic). For immunofluorescence detection
of FADD, gH2A.X and CD95, the antibodies described above were used.
Fluorescent secondary antibodies directed to mouse and rabbit (Alexa488 and
Alexa594) were purchased from Molecular Probes (Invitrogen).
RNA interference methodology
Silencing of protein expression in HCT116 cells was accomplished by
transfection of 21-nucleotide RNA duplexes. Transfection of CD95
(L-0,03,776-00), DR5 (L-0,04,448-00) and control (D-0,01,810-10) ON-
TARGET-plus SMARTpool siRNAs (Thermo Fisher Scientific) was performed
using the INTERFERin transfection reagent (Polyplus transfection) accord-
ing to the instructions of the manufacturer. Similarly, ATM was targeted by
a pool of siRNAs (Flexitube siATM-8, -9 and -12), each individually
purchased from Qiagen (Hilden, Germany) 1919. Briefly, 4 105 cells were
transfected in normal cell medium using 10 nM final concentration of siRNA
and 3.65ml/ml INTERFERin.
Isolation of membrane proteins
Cells were treated as indicated in figures, and proteins found in cytosolic
and membrane fractions were isolated using the Qproteome Cell
Compartment Kit (Qiagen) according to the instructions of the manufac-
turer. Enrichment of DISC-containing proteins in cellular membranes was
then assayed by SDS–PAGE.
Vectors and cloning
The wt p53 and p53 (S15A) cDNAs were kindly provided by Professor Moshe
Oren (Weizmann Institute of Science, Rehovot, Israel). Subsequent to deletion
of the stop codons in order to allow for green fluorescent protein expression,
wt and mutated p53 sequences were subcloned into the Xba1–BamH1 site of
the pCDH–CMV–MCS–EF1–copGFP expression vector (System Biosciences,
Mountain View, CA, USA). Lentiviral packaging was accomplished by using the
LentiSuite according to the instructions of the manufacturer (System
Biosciences). Then, transductions of HCT116 p53 / cells were performed
by incubation at normal culturing conditions in the presence of virus for 24h.
Ca2þ measurements
Intracellular Ca2þ levels were monitored by using the Fluo-4AM
fluorescent indicator (Invitrogen). In brief, 4 mM of the Ca2þ probe was
added to cells 30min in advance of 5-FU treatment. Time-lapse analysis of
living cells was then performed using the Zeiss LSM 510 META confocal
laser scanner microscope or the FACS Calibur system in combination with
the CellQuest v.3.3 software (Becton-Dickinson, San Jose, CA, USA).
ABBREVIATIONS
Ca2þ , calcium; DISC, death-inducing signaling complex; 5-FU,
5-fluorouracil.
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